SPILLO supports pharmaceutical and biotech R&D teams through unbiased, in silico, proteome-wide identification of targets and off-targets. Using exclusive, experimentally validated, physics-based computational technology, SPILLO reduces scientific risk and clarifies mechanisms in drug development.
Products, services, technology
Unbiased, in silico, physics-based computational analysis of the structural proteome to identify targets and off-targets for small molecules. Services support mechanism elucidation, anticipation of safety liabilities (including rare ADRs), drug rescue, repurposing, and informed R&D decisions.
Cooperation possibilities
Project-based collaborations with pharmaceutical and established biotech companies seeking deep mechanistic insight to support internal R&D decisions, safety assessment, and development strategy for existing drug candidates.
- https://www.spillo.ch
- +41 76 626 83 00
- Send an email
- Alessandro Di Domizio
Some insights
By uncovering the biomolecular mechanisms behind drug efficacy and adverse effects, SPILLO helps make medicines safer, more effective, and better targeted. Mechanistic insight enables earlier risk reduction, fewer late-stage failures, and more informed, patient-tailored development strategies.
We are proud to deliver unbiased scientific insights that others miss—validated experimentally and trusted in real-world drug development challenges—helping partners make better decisions when the stakes are highest.
We look up to organizations that combine scientific rigor with responsibility, transparency, and long-term impact—advancing drug development through deep understanding rather than black-box approaches.
By facilitating qualified connections with pharmaceutical, biotech, and government research organizations facing complex mechanistic or safety challenges in applied drug development, and by increasing visibility among R&D decision-makers.
Pharmaceutical and biotech R&D, translational science, and drug safety teams, as well as public or government research institutes engaged in applied drug development programs for small-molecule therapeutics.
